Navigation Links
Leading Pharmaceutical Marketing Research and Consulting Company Introduces 'Intelligent Efficiency' Program

BLUE BELL, Pa., Feb. 1, 2012 /PRNewswire/ -- Evolution Marketing Research, the next generation pharmaceutical marketing research and consulting company, announced that it has proactively restructured in order to better take advantage of the evolving global pharmaceutical marketplace in coming years. As a keystone of this restructuring, the company has instituted a new strategy called "Intelligent Efficiency." This strategy is intended to allow the company to compete effectively in this new market environment with a streamlined organizational structure.

"Over the past decade, the pharmaceutical marketing research industry has known nothing but solid, often dramatic, growth. The pharmaceutical industry, however, has changed and the new definition of success in these trying economic times is stability rather than growth, in large part due to shrinking pharma marketing research budgets," said company Principal James Cummings

Evolution's founding principals look forward to a more stable market environment in the year to come which will allow for the development of new relationships in the biopharma industry. "By every definition of the term, Evolution had a stable year and is poised for success in the future," explains Daniel Slawe, Chief Operating Officer. "The restructuring of the company under our new Intelligent Efficiency program will allow us to continue to provide best-in-class service to our clients."

An important part of this drive will be the development of new and innovative research methodologies and products. "Evolution is constantly in the process of creating new key products, several of which will be launching over the course of this year [2012]," said Principal Dr. James Heasley. "This is in keeping with our corporate mission of continuing to innovate and lead in an industry that is always seeking to enhance efficiencies." In 2011, the company introduced a range of innovative methodologies such as the well-received PreSIM(SM) qualitative conjoint method and its ActiveInsight™ custom omnibus study. 

Through the Intelligent Efficiency initiative, Evolution is committed to introduction of new and original methodologies geared toward aiding clients to make the most of their resources.

About Evolution Marketing Research, LLC:

Evolution Marketing Research is a medical marketing research firm that provides qualitative and quantitative research, consulting services, project management, advisory board monitoring and other marketing research services to pharmaceutical, biotech and medical device companies all over the world. Company Principals John Taenzler, Ph.D., Jim Cummings, and James Heasley, Ph.D., who are backed by a seasoned team of analysts and researchers, bring their collective experience to bear on pharmaceutical projects at all phases of the product lifecycle, including opportunity and licensing assessments, product crafting in support of phase III clinical trial design, and development of the commercial platform for developmental and in-line products. To learn more, call (866) 486-0873 or visit  


Inna Lobanova-Heasley

This press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at

SOURCE Evolution Marketing Research, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. iBioSeminars and iBioMagazine: Free, Online Biology Seminars and Short Talks by Leading Scientists
2. Northwest Bio Reaffirms Its Freedom to Operate; Refutes Other Parties Misleading Patent Assertions
3. BioSpace Spotlights Leading Life Science Community
4. Leading Investigator to Present Clinical Data on Generex Oral-lyn™ at International Diabetes Federation Meetings in Dubai
5. CenTrak, a Leading Real-Time Location System Provider, Unveils New Branding
6. Oral Therapy Teriflunomide (Aubagio™(*)) Significantly Reduces Relapses Leading to Hospitalization of Patients with Multiple Sclerosis
7. CTRI Confirms Leading Indian CRO Supports Majority of Hemophilia Trials in India
8. Californias Industrial Biotechnology Workforce: Creating Jobs and Leading Innovation
9. OncoGenex Announces Publication of Custirsen Phase II Clinical and Pre-Clinical Data in Leading Cancer Journals
10. Clinical Integration Enables Leading Health Systems to Deliver Higher Quality, Cost-Effective Care
11. Leading Life Sciences Luminaries Connect at Innovation Ireland Reception
Post Your Comments:
(Date:11/27/2015)... November 27, 2015 ... popularity of companion diagnostics is one of ... market with pharmaceutical companies and diagnostic manufacturers ... tests. . --> ... report on global cancer biomarkers market spread ...
(Date:11/25/2015)... , Nov. 25, 2015  PharmAthene, Inc. (NYSE MKT: ... adopted a stockholder rights plan (Rights Plan) in an ... loss carryforwards (NOLs) under Section 382 of the Internal ... --> PharmAthene,s use of its NOLs could be ... as defined in Section 382 of the Code. In ...
(Date:11/25/2015)... , Nov. 25, 2015  Neurocrine Biosciences, Inc. ... Gorman , President and CEO of Neurocrine Biosciences, will ... Conference in New York . ... visit the website approximately 5 minutes prior to the ... replay of the presentation will be available on the ...
(Date:11/25/2015)... PORTLAND, Oregon , November 25, 2015 /PRNewswire/ ... Deep Market Research Report is a professional and ... Genomics industry.      (Logo: ... basic overview of the industry including definitions, classifications, ... analysis is provided for the international markets including ...
Breaking Biology Technology:
(Date:11/10/2015)... 10, 2015  In this report, the ... of product, type, application, disease indication, and ... report are consumables, services, software. The type ... biomarkers, efficacy biomarkers, and validation biomarkers. The ... diagnostics development, drug discovery and development, personalized ...
(Date:11/2/2015)... Calif. , Nov. 2, 2015  SRI International ... million to provide preclinical development services to the National ... contract, SRI will provide scientific expertise, modern testing and ... variety of preclinical pharmacology and toxicology studies to evaluate ... --> The PREVENT Cancer Drug Development Program ...
(Date:10/29/2015)... , Oct. 29, 2015  Connected health pioneer, ... driving the explosion of technology-enabled health and wellness, and ... new book, The Internet of Healthy Things ... sensors or smartphones even existed, Dr. Kvedar, vice president, ... of health care delivery, moving care from the hospital ...
Breaking Biology News(10 mins):